Skip to content

Eleven (NASDAQ: EBIO), founded in 2008, is a publicly-traded late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on its Targeted Protein Therapeutics (TPTs) platform. The company raised a $50M IPO in 2014 and changed its name to Sesen Bio in 2018.

Latest Press from Eleven Biosciences

Next